Perspectives of pharmacotherapy in Alzheimer's disease

Kiyofumi Yamada, Xiuhai Ren, Toshitaka Nabeshima

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and it is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein. Genetic, molecular biological and neuropharmacological evidence support the 'amyloid cascade hypothesis' for the pathogenesis of the disease. We review the in vivo effects of various compounds on behavioral and neuropathological changes in the non-transgenic animal models of AD produced by continuous i.c.v. infusion of Aβ. These results support therapeutic strategies such as cholinergic therapy, anti-inflammatory agents, antioxidants and estrogen replacement therapy, as well as other cognition enhancers for the treatment of AD. In addition, the amyloid cascade hypothesis offers a number of potential targets for novel therapeutic strategies in AD. We believe that our non-transgenic animal model, as well as transgenic animal models, are useful for developing novel pharmacotherapeutics in AD.

Original languageEnglish
Pages (from-to)9-14
Number of pages6
JournalJapanese Journal of Pharmacology
Volume80
Issue number1
DOIs
Publication statusPublished - 22-06-1999

Fingerprint

Alzheimer Disease
Drug Therapy
Amyloid
Animal Models
Amyloid Plaques
Cognition
Neurofibrillary Tangles
Genetically Modified Animals
Peptide Fragments
Estrogen Replacement Therapy
Amyloid beta-Protein Precursor
Therapeutics
Cholinergic Agents
Molecular Biology
Anti-Inflammatory Agents
Antioxidants
Amino Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Yamada, Kiyofumi ; Ren, Xiuhai ; Nabeshima, Toshitaka. / Perspectives of pharmacotherapy in Alzheimer's disease. In: Japanese Journal of Pharmacology. 1999 ; Vol. 80, No. 1. pp. 9-14.
@article{65407b381e6646ef82e05ce5e32e3d82,
title = "Perspectives of pharmacotherapy in Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and it is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein. Genetic, molecular biological and neuropharmacological evidence support the 'amyloid cascade hypothesis' for the pathogenesis of the disease. We review the in vivo effects of various compounds on behavioral and neuropathological changes in the non-transgenic animal models of AD produced by continuous i.c.v. infusion of Aβ. These results support therapeutic strategies such as cholinergic therapy, anti-inflammatory agents, antioxidants and estrogen replacement therapy, as well as other cognition enhancers for the treatment of AD. In addition, the amyloid cascade hypothesis offers a number of potential targets for novel therapeutic strategies in AD. We believe that our non-transgenic animal model, as well as transgenic animal models, are useful for developing novel pharmacotherapeutics in AD.",
author = "Kiyofumi Yamada and Xiuhai Ren and Toshitaka Nabeshima",
year = "1999",
month = "6",
day = "22",
doi = "10.1254/jjp.80.9",
language = "English",
volume = "80",
pages = "9--14",
journal = "Japanese Journal of Pharmacology",
issn = "0021-5198",
publisher = "Japanese Pharmacological Society",
number = "1",

}

Perspectives of pharmacotherapy in Alzheimer's disease. / Yamada, Kiyofumi; Ren, Xiuhai; Nabeshima, Toshitaka.

In: Japanese Journal of Pharmacology, Vol. 80, No. 1, 22.06.1999, p. 9-14.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Perspectives of pharmacotherapy in Alzheimer's disease

AU - Yamada, Kiyofumi

AU - Ren, Xiuhai

AU - Nabeshima, Toshitaka

PY - 1999/6/22

Y1 - 1999/6/22

N2 - Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and it is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein. Genetic, molecular biological and neuropharmacological evidence support the 'amyloid cascade hypothesis' for the pathogenesis of the disease. We review the in vivo effects of various compounds on behavioral and neuropathological changes in the non-transgenic animal models of AD produced by continuous i.c.v. infusion of Aβ. These results support therapeutic strategies such as cholinergic therapy, anti-inflammatory agents, antioxidants and estrogen replacement therapy, as well as other cognition enhancers for the treatment of AD. In addition, the amyloid cascade hypothesis offers a number of potential targets for novel therapeutic strategies in AD. We believe that our non-transgenic animal model, as well as transgenic animal models, are useful for developing novel pharmacotherapeutics in AD.

AB - Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and it is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein. Genetic, molecular biological and neuropharmacological evidence support the 'amyloid cascade hypothesis' for the pathogenesis of the disease. We review the in vivo effects of various compounds on behavioral and neuropathological changes in the non-transgenic animal models of AD produced by continuous i.c.v. infusion of Aβ. These results support therapeutic strategies such as cholinergic therapy, anti-inflammatory agents, antioxidants and estrogen replacement therapy, as well as other cognition enhancers for the treatment of AD. In addition, the amyloid cascade hypothesis offers a number of potential targets for novel therapeutic strategies in AD. We believe that our non-transgenic animal model, as well as transgenic animal models, are useful for developing novel pharmacotherapeutics in AD.

UR - http://www.scopus.com/inward/record.url?scp=0032972171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032972171&partnerID=8YFLogxK

U2 - 10.1254/jjp.80.9

DO - 10.1254/jjp.80.9

M3 - Review article

C2 - 10446751

AN - SCOPUS:0032972171

VL - 80

SP - 9

EP - 14

JO - Japanese Journal of Pharmacology

JF - Japanese Journal of Pharmacology

SN - 0021-5198

IS - 1

ER -